Agenus Inc. — Form 10-Q Summary
Business context and reporting period
Reports the quarter and nine months ended September 30, 2014. Agenus is an immuno-oncology company developing checkpoint-modulator antibodies, heat-shock-protein vaccines, and vaccine adjuvants. The February 2014 acquisition of 4-Antibody AG added the Retrocyte Display platform and six preclinical antibody programs.
Financial results and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $1.56 million | $0.74 million | $5.36 million | $2.65 million |
| Research and development expense | $5.28 million | $3.89 million | $14.98 million | $9.76 million |
| General and administrative expense | $4.92 million | $3.58 million | $16.21 million | $11.11 million |
| Operating loss | $7.67 million | $6.81 million | $26.00 million | $18.75 million |
| Net loss | $8.11 million | $7.32 million | $16.51 million | $24.30 million |
| Net loss attributable to common stockholders per share | $(0.13) | $(0.24) | $(0.28) | $(0.99) |
At September 30, 2014, cash and cash equivalents were $38.4 million and short-term investments were $14.5 million, totaling $52.9 million. Current assets were $55.2 million and current liabilities $15.6 million. Total assets were $87.6 million; stockholders’ equity was $48.9 million. Debt principal outstanding was $7.1 million, with the reported debt balance classified as current. Accumulated deficit was $665.3 million.
For the first nine months, operating cash use was $27.7 million, versus $14.0 million in 2013; investing cash use was $15.1 million, and financing provided $53.5 million. Cash increased by $11.0 million from year-end 2013. The filing does not provide a clear gross-margin measure; service revenue was zero in 2014.
Material changes and unusual items
- Nine-month revenue roughly doubled, including grant revenue and license/milestone revenue; 4-Antibody contributed $2.1 million of revenue and $5.1 million of net loss for the period after acquisition.
- Operating loss widened as R&D and administrative expenses rose, reflecting the acquisition, higher staffing and compensation, antibody-program spending, and corporate professional fees.
- Nine-month net loss improved despite the larger operating loss, mainly because non-operating income included a $10.8 million reduction in the fair value of the contingent royalty obligation, largely following GSK’s termination of its Phase 3 MAGE-A3 lung-cancer trial. The obligation was $7.6 million at period-end.
- In February, Agenus raised approximately $56.2 million net through a public offering of 22.2 million shares. The 4-Antibody acquisition consideration included 3.3 million shares and contingent payments with an estimated $9.9 million period-end fair value and potential milestones of up to $40 million.
- In October, after quarter-end, Agenus put in place an effective shelf registration for up to $150 million of securities, including an at-the-market program for up to 10 million shares. No assurance was given that shares would be sold.
Outlook, commentary and risks
Management said cash, cash equivalents and short-term investments, together with potential proceeds from existing agreements, were expected to fund requirements through the first half of 2015. Agenus expected to seek additional financing before funds were depleted and said it could reduce spending or operations if necessary. It warned that failure to raise capital could threaten continued operations. No specific earnings or revenue guidance was provided.
Management planned to advance selected GITR and CTLA-4 antibody candidates toward IND-enabling work, identify candidates in other programs, and seek partners for HerpV and other programs. The Merck antibody-discovery collaboration carried potential milestone payments of approximately $100 million plus royalties, subject to achieving milestones and eventual product sales. GSK had submitted a European marketing application for a malaria vaccine containing QS-21; partners’ clinical, regulatory and commercial success remains outside Agenus’s control.
Key risks include continuing operating losses and financing needs; debt repayments due in April 2015; clinical, regulatory, manufacturing and partnering uncertainty; competition and intellectual-property challenges; and dependence on licensees for potential QS-21 revenue. The filing reported effective disclosure controls and no material third-quarter change in internal control, while integration of 4-Antibody’s controls was ongoing. Foreign-currency exposure increased with 4-Antibody operations in Switzerland and Germany; Agenus reported no hedging strategy.
Important facts for investors to verify
- Whether the stated cash runway through the first half of 2015 remains achievable given operating cash use and near-term debt maturities.
- Any actual ATM or other financing activity, resulting dilution, and updated share count.
- Progress and enrollment/data updates for the Prophage, HerpV and checkpoint-antibody programs, and whether partnerships or milestones generate cash.
- Effects of GSK’s MAGE-A3 trial termination on contingent royalty valuations and future QS-21 revenue prospects.
- Final 4-Antibody purchase-price allocation and any changes to contingent obligations or acquisition integration costs.